Funded by The National Institute of Biomedical Imaging and Bioengineering
We design, manufacture, and deliver new tools to the biomedical community that utilize liquid biopsies for disease detection and management.
What is Precision Medicine?
The "Precision Medicine" initiative was announced by President Obama in his 2016 State of the Union address.
The initiative aims to shift away from a generic treatment approach to customizing medications for individuals. This tailored approach ensures that patients receive the most effective and safe treatments by targeting the specific characteristics of their illness.
CBM² is contributing to the Precision Medicine initiative by developing advanced tools that can rapidly deliver crucial diagnostic and prognostic information, overcoming current testing limitations.
As President Obama envisioned, this initiative strives to deliver "the right treatment at the right time."
Plastics Engineering
Designing and fabricating microfluidic and nanofluidic devices in thermoplastics.
Learn more about Plastics Engineering
Liquid Biopsy Analysis
Performing highly efficient isolation and molecular analysis (CTCs, EVs, cfDNA).
Learn more about Liquid Biopsy AnalysisCBM² Stories
American Chemical Society Journal Publishes New Article from Dr. Park
Nature Biotechnology Journal Publishes New Article on Ovarian Cancer Cells with Contributions from Dr. Godwin
Proteoglycan Research Journal Publishes New Article from Dr. Hall
Dr. Soper Hosts Training Course, Gives Keynote Presentation at SelectBio World Congress
Upcoming Events
Organization Statistics
Work with us
The Center is excited to accept requests for collaboration projects with researchers in the biomedical and microfluidics community.
Collaboration & Service Projects